RESUMEN
Several studies have evaluated the impact of low dose statin (20-80 mg/day) on bone metabolism with inconclusive results despite promising data of preclinical studies. In this study, we investigated the effect of high dose simvastatin (HD-Sim) on biochemical markers of bone turnover and disease activity in six heavily pretreated patients with multiple myeloma (MM). These patients were treated with simvastatin (15 mg/kg/day) for 7 days followed by a rest period of 21 days in two 4-week cycles. Endpoints were changes in the level of biochemical markers of (i) osteoclast activity (tartrate resistant acid phosphatase, TRACP); (ii) bone resorption (collagen fragments CTX and NTX); (iii) bone formation (osteocalcin and aminoterminal propeptide of type I collagen PINP); (iv) cholesterol; (v) regulators of bone metabolism [osteoprotegerin (OPG) and Dickkopf-1 (DKK-1)] and (vi) disease activity (monoclonal proteins or free light chains in serum). TRACP activity in serum and levels of collagen fragments (NTX) in urine increased for all patients temporarily during the 7 days of treatment with HD-Sim indicating that osteoclasts may have been stimulated rather than inhibited. The other markers of bone metabolism showed no change. None of the patients showed any reduction in free monoclonal light chains or monoclonal proteins in serum during treatment with HD-Sim. In spite of the fact that bone turn over effects of HD-Sim may have been blunted by concomitant treatment of patients with other drugs we observed a transient increase in markers of osteoclast activity. This sign of a transient stimulation of osteoclast activity suggests that HD-Sim may be harmful rather than beneficial for MM patients. For this reason and because of gastro-intestinal side effects the study was stopped prematurely.
Asunto(s)
Huesos/metabolismo , Mieloma Múltiple/tratamiento farmacológico , Mieloma Múltiple/metabolismo , Simvastatina/toxicidad , Simvastatina/uso terapéutico , Anciano , Anciano de 80 o más Años , Huesos/efectos de los fármacos , Esquema de Medicación , Quimioterapia Combinada , Femenino , Humanos , Hipolipemiantes/uso terapéutico , Hipolipemiantes/toxicidad , Masculino , Persona de Mediana Edad , Osteoclastos/efectos de los fármacos , Osteoclastos/metabolismo , Selección de PacienteRESUMEN
Bone development requires the recruitment of osteoclast precursors from surrounding mesenchyme, thereby allowing the key events of bone growth such as marrow cavity formation, capillary invasion, and matrix remodeling. We demonstrate that mice deficient in gelatinase B/matrix metalloproteinase (MMP)-9 exhibit a delay in osteoclast recruitment. Histological analysis and specialized invasion and bone resorption models show that MMP-9 is specifically required for the invasion of osteoclasts and endothelial cells into the discontinuously mineralized hypertrophic cartilage that fills the core of the diaphysis. However, MMPs other than MMP-9 are required for the passage of the cells through unmineralized type I collagen of the nascent bone collar, and play a role in resorption of mineralized matrix. MMP-9 stimulates the solubilization of unmineralized cartilage by MMP-13, a collagenase highly expressed in hypertrophic cartilage before osteoclast invasion. Hypertrophic cartilage also expresses vascular endothelial growth factor (VEGF), which binds to extracellular matrix and is made bioavailable by MMP-9 (Bergers, G., R. Brekken, G. McMahon, T.H. Vu, T. Itoh, K. Tamaki, K. Tanzawa, P. Thorpe, S. Itohara, Z. Werb, and D. Hanahan. 2000. Nat. Cell Biol. 2:737-744). We show that VEGF is a chemoattractant for osteoclasts. Moreover, invasion of osteoclasts into the hypertrophic cartilage requires VEGF because it is inhibited by blocking VEGF function. These observations identify specific actions of MMP-9 and VEGF that are critical for early bone development.
Asunto(s)
Desarrollo Óseo/fisiología , Factores de Crecimiento Endotelial/fisiología , Linfocinas/fisiología , Metaloproteinasa 9 de la Matriz/metabolismo , Osteoclastos/fisiología , Animales , Desarrollo Óseo/efectos de los fármacos , Resorción Ósea , Quimiotaxis , Cruzamientos Genéticos , Heterocigoto , Metaloproteinasa 9 de la Matriz/deficiencia , Metaloproteinasa 9 de la Matriz/genética , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Osteoclastos/citología , Osteoclastos/efectos de los fármacos , Inhibidores de Proteasas/farmacología , Factor A de Crecimiento Endotelial Vascular , Factores de Crecimiento Endotelial VascularRESUMEN
OBJECTIVE: Cartilage degradation in osteoarthritis (OA) generates the type II collagen fragments, Helix-II and CTX-II that can be used as clinical biological markers. Helix-II and C-telopeptide of type II collagen (CTX-II) levels are associated independently with progression of OA suggesting that they may be generated through different collagenolytic pathways. In this study we analyzed the release of Helix-II and CTX-II from human cartilage collagen by the proteinases reported to play a role in cartilage degradation. METHODS: In vitro, human articular cartilage extract was incubated with activated human recombinant cathepsins (Cats) and matrix-metalloproteases (MMPs). Next, we analyzed the spontaneous release of Helix-II and CTX-II from cartilage sections of patients with knee OA who were immediately deep frozen after joint replacement to preserve endogenous enzyme activity until assay. Cartilage sections were then incubated for up to 84 h in the presence or absence of E-64 and GM6001, inhibitors of cysteine proteases and MMPs, respectively. RESULTS: In vitro, Cats K, L and S generated large amount of Helix-II, but not CTX-II. Cat B generated CTX-II fragment, but destroyed Helix-II immunoreactivity. Cat D was unable to digest intact cartilage. MMPs-1, -3, -7, -9, and -13 efficiently released CTX-II, but only small amount of Helix-II. Neither CTX-II nor Helix-II alone was able to reflect accurately the collagenolytic activity of Cats and MMPs as reflected by the release of hydroxyproline. In OA cartilage explants, E-64 blunted the release of Helix-II whereas the release of CTX-II could be completely abrogated by GM6001 and only partly by E-64. CONCLUSION: These in vitro and ex vivo experiments of human cartilage suggest that Helix-II and CTX-II could be released in part by different enzymatic pathways. Helix-II and CTX-II alone reflect only partially overall cartilage collagen degradation. These findings may explain why these two biological markers could provide complementary information on disease progression in OA.
Asunto(s)
Cartílago Articular/patología , Catepsinas/metabolismo , Colágeno Tipo II/metabolismo , Metaloproteinasas de la Matriz/metabolismo , Osteoartritis de la Rodilla/patología , Biomarcadores/metabolismo , Humanos , Valor Predictivo de las PruebasRESUMEN
Myeloma bone disease is due to bone degradation by osteoclasts, and absence of repair by bone forming osteoblasts. Recent observations suggest that the anti-myeloma drug bortezomib, a proteasome inhibitor, stimulates bone formation and may inhibit bone resorption. Here, we tested bortezomib on cultured osteoclasts in conditions mimicking the pulse treatment used in the clinic, thereby avoiding continuous proteasome inhibition and unselective toxicity. A 3 h pulse with 25 nM bortezomib followed by a 3-day culture in its absence markedly inhibited osteoclast activity as evaluated through bone resorption, TRAcP release, and RANKL-induced NF-kappaB translocation into nuclei, an event dependent on proteasomes and critical for osteoclast function. The effect on TRAcP was maximal during the first 24 h post-pulse, and then tended to subside. Importantly, applying this pulse treatment to cultured myeloma cells drastically reduced their survival. We measured next the levels of two bone resorption markers in patients during the 3 days following five and seven therapeutic bortezomib administrations, respectively. These levels decreased significantly already 1-2 days after injection, and then increased, showing temporary inhibition of osteoclast activity and paralleling the in vitro effect on TRAcP. Our study demonstrates a direct inhibition of osteoclasts by bortezomib in conditions relevant to treatment of myeloma.
Asunto(s)
Antineoplásicos/administración & dosificación , Resorción Ósea/tratamiento farmacológico , Ácidos Borónicos/administración & dosificación , Mieloma Múltiple/tratamiento farmacológico , Osteoclastos/efectos de los fármacos , Pirazinas/administración & dosificación , Antineoplásicos/farmacología , Resorción Ósea/metabolismo , Ácidos Borónicos/farmacología , Bortezomib , Núcleo Celular/metabolismo , Proliferación Celular , Humanos , Mieloma Múltiple/metabolismo , Mieloma Múltiple/patología , FN-kappa B/antagonistas & inhibidores , FN-kappa B/genética , FN-kappa B/metabolismo , Osteoblastos/efectos de los fármacos , Osteoclastos/metabolismo , Complejo de la Endopetidasa Proteasomal/metabolismo , Inhibidores de Proteasoma , Quimioterapia por Pulso , Pirazinas/farmacología , Ligando RANK/farmacología , ARN Mensajero/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Transducción de Señal , Células Tumorales CultivadasRESUMEN
The cell surface expression of CD9, a glycoprotein of the tetraspanin family influencing several processes including cell motility and metastasis, inversely correlates with progression in several solid tumors. In the present work, we studied the expression and role of CD9 in multiple myeloma (MM) biology using the 5T33MM mouse model. The 5T33MMvitro cells were found to be CD9 negative. Injection of these cells in mice caused upregulation of CD9 expression, while reculturing them resulted in downregulation of CD9. Coculturing of CD9-negative 5T33MMvitro cells with BM endothelial cells (BMECs) resulted in a partial retrieval of CD9. Laser microdissection followed by real-time polymerase chain reaction and immunohistochemistry performed on bone sections of 5T33MMvivo diseased mice demonstrated strong local expression of CD9 on MM cells in contact with BMEC compared to MM cells further away. These findings were also confirmed by immunohistochemistry in MM patients. Neutralizing anti-CD9 antibodies inhibited transendothelial invasion of CD9-expressing human MM5.1 and murine 5T33MMvivo cells. In conclusion, we provide evidence that CD9 expression by the MM cells is upregulated in vivo by close interaction of the cells with BMEC and that CD9 is involved in transendothelial invasion, thus possibly mediating homing and/or spreading of the MM cells.
Asunto(s)
Antígenos CD/metabolismo , Células Endoteliales/metabolismo , Células Endoteliales/patología , Glicoproteínas de Membrana/metabolismo , Mieloma Múltiple/metabolismo , Mieloma Múltiple/patología , Animales , Antígenos CD/genética , Biopsia , Células de la Médula Ósea/metabolismo , Células de la Médula Ósea/patología , Comunicación Celular , Línea Celular Tumoral , Modelos Animales de Enfermedad , Citometría de Flujo , Regulación Neoplásica de la Expresión Génica , Humanos , Inmunohistoquímica , Glicoproteínas de Membrana/genética , Ratones , Ratones Endogámicos C57BL , Mieloma Múltiple/fisiopatología , Invasividad Neoplásica , Tetraspanina 29 , Regulación hacia ArribaRESUMEN
The molecular mechanisms by which tumor cells metastasize to bone are likely to involve invasion, cell adhesion to bone, and the release of soluble mediators from tumor cells that stimulate osteoclast-mediated bone resorption. Bisphosphonates (BPs) are powerful inhibitors of the osteoclast activity and are, therefore, used in the treatment of patients with osteolytic metastases. However, an added beneficial effect of BPs may be direct antitumor activity. We previously reported that BPs inhibit breast and prostate carcinoma cell adhesion to bone (Boissier et al., Cancer Res., 57: 3890-3894, 1997). Here, we provided evidence that BP pretreatment of breast and prostate carcinoma cells inhibited tumor cell invasion in a dose-dependent manner. The order of potency for four BPs in inhibiting tumor cell invasion was: zoledronate > ibandronate > NE-10244 (active pyridinium analogue of risedronate) > clodronate. In addition, NE-58051 (the inactive pyridylpropylidene analogue of risedronate) had no inhibitory effect, whereas NE-10790 (a phosphonocarboxylate analogue of risedronate in which one of the phosphonate groups is substituted by a carboxyl group) inhibited tumor cell invasion to an extent similar to that observed with NE-10244, indicating that the inhibitory activity of BPs on tumor cells involved the R2 chain of the molecule. BPs did not induce apoptosis in tumor cells, nor did they inhibit tumor cell migration at concentrations that did inhibit tumor cell invasion. However, although BPs did not interfere with the production of matrix metalloproteinases (MMPs) by tumor cells, they inhibited their proteolytic activity. The inhibitory effect of BPs on MMP activity was completely reversed in the presence of an excess of zinc. In addition, NE-10790 did not inhibit MMP activity, suggesting that phosphonate groups of BPs are responsible for the chelation of zinc and the subsequent inhibition of MMP activity. In conclusion, our results provide evidence for a direct cellular effect of BPs in preventing tumor cell invasion and an inhibitory effect of BPs on the proteolytic activity of MMPs through zinc chelation. These results suggest, therefore, that BPs may be useful agents for the prophylactic treatment of patients with cancers that are known to preferentially metastasize to bone.
Asunto(s)
Neoplasias Óseas/secundario , Neoplasias de la Mama/tratamiento farmacológico , Difosfonatos/farmacología , Neoplasias de la Próstata/tratamiento farmacológico , Antineoplásicos Fitogénicos/farmacología , Apoptosis , Adhesión Celular , Ciclo Celular/efectos de los fármacos , Movimiento Celular , Ácido Clodrónico/farmacología , Colágeno/metabolismo , Relación Dosis-Respuesta a Droga , Combinación de Medicamentos , Citometría de Flujo , Fluorometría , Humanos , Ácido Ibandrónico , Imidazoles/farmacología , Laminina/metabolismo , Masculino , Metaloproteinasas de la Matriz/metabolismo , Invasividad Neoplásica , Metástasis de la Neoplasia , Paclitaxel/farmacología , Proteoglicanos/metabolismo , Piridinas/farmacología , Compuestos de Piridinio/farmacología , Células Tumorales Cultivadas , Zinc/metabolismo , Ácido ZoledrónicoRESUMEN
The subcellular localization of the omega-hydroxylase of Saccharomycopsis lipolytica was assessed by the analytical fractionation technique, originally described by de Duve C., Pressman, B.C., Gianetto, R., Wattiaux, R. and Appelmans, F., and hitherto little, if at all, applied to yeasts. Protoplasts were separated in six fractions by differential centrifugation. Some of these fractions were further fractionated by density gradient centrifugation. The distribution of omega-hydroxylase and 15 other constituents chosen as possible markers of its subcellular entities. (1) Mitochondria were characterized by particulate malate dehydrogenase, particulate Antimycin A-insensitive NADH-cytochrome c reductase, oligomycin-sensitive and K+-stimulated ATPase pH 9. (2) Most if not all of the catalase and urate oxidase is peroxisomal. (3) Free ribosomes account for most RNA. (4) Nucleoside diphosphatase is for the first time reported in a yeast and appears to belong to an homogeneous population of small membranes. (5) The soluble compartment contains magnesium pyrophosphatase, alkaline, 5'-nucleotidase and part of the NADH-cytochrome c reductase. Latent arylesterase and ATPase pH 7 have an unspecific distribution. Alkaline phosphodiesterase I has not been detected.
Asunto(s)
Alcanos/metabolismo , Ascomicetos/enzimología , Oxigenasas de Función Mixta/análisis , Saccharomycopsis/enzimología , Citocromo P-450 CYP4A , Sistema Enzimático del Citocromo P-450/análisis , Esterasas/análisis , Ácidos Grasos/análisis , Membranas Intracelulares/enzimología , Cinética , NADPH-Ferrihemoproteína Reductasa/análisis , Oxidorreductasas/análisis , Monoéster Fosfórico Hidrolasas/análisis , Protoplastos/enzimología , Fracciones Subcelulares/enzimologíaRESUMEN
1. Active mouse bone collagenase is excluded from its inhibitory antibody by preincubation of that antibody with various forms of inactive enzyme, e.g. 'procollagenase', some collagenase-inhibitor complexes or partially denatured or degraded collagenase. This property allows the detection of several enzymatically inactive forms of collagenase. 2. The accumulation of immunoreactive collagenase in the culture fluid of mouse bones occurred only in the presence of heparin and was not correlated with bone resorption induced by parathyroid hormone. These experiments provide further (see Lenaers-Claeys, G. and Vaes, G., Biochim. Biophys. Acta (1979) 584, 375-388), more conclusive evidence that the critical role in the resorption of the organic matrix of these explants may be due to another enzyme system than collagenase.
Asunto(s)
Resorción Ósea , Huesos/enzimología , Colagenasas , Colagenasa Microbiana/inmunología , Animales , Células Cultivadas , Precursores Enzimáticos/metabolismo , Heparina/metabolismo , Inmunoglobulina G/metabolismo , Ratones , Colagenasa Microbiana/antagonistas & inhibidores , Colagenasa Microbiana/metabolismo , Conejos , Tripsina/metabolismoRESUMEN
An attempt was made to establish whether the activation of plasminogen into plasmin is necessary either for the preparatory phases to bone resorption, involving the recruitment of osteoclast precursors, their migration toward mineralized surfaces, and their final differentiation, or for the subsequent osteoclastic resorption phase. 45Ca-labeled fetal (17 day) mouse metatarsals were cultured under conditions in which they pursue their modeling for a few days. In this model, the resorption phase, monitored by the release of 45Ca into the medium, is entirely dependent on the preparatory phases affecting osteoclast precursors. It was, as expected, stimulated by parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D3 and inhibited by calcitonin. PTH also enhanced the activity of tissue-type plasminogen activator (PA) in extracts of metatarsals but not that of urokinase (which is, however, the main PA present in the mouse fetal metatarsal culture model). The resorption processes were not dependent on the presence of plasminogen in the media, even when the rudiments were precultured with tranexamic acid to remove their endogenous plasminogen. Moreover, they were not influenced by inhibitors of plasmin, either the plasma inhibitors alpha 2-antiplasmin, alpha 2-macroglobulin, and alpha 1-antitrypsin, or aprotinin, which was tested under a variety of conditions. Aprotinin also did not influence the resorption (loss of calcium and hydroxyproline) of 19 day fetal mouse calvariae cultured with PTH in a medium devoid of plasminogen. It is concluded that the various steps implicated in the bone resorption processes that occur in the metatarsals and in the calvariae culture models are not dependent on the activity of plasmin. The function of PAs in bone, however, could be exerted through direct proteolysis of extracellular proteins other than plasminogen or be mediated by a molecular structural domain distinct from their catalytic domain.
Asunto(s)
Resorción Ósea/etiología , Fibrinolisina/metabolismo , Osteoclastos/metabolismo , Activadores Plasminogénicos/metabolismo , Animales , Densidad Ósea/efectos de los fármacos , Resorción Ósea/metabolismo , Calcitonina/farmacología , Calcitriol/farmacología , Diferenciación Celular/efectos de los fármacos , Diferenciación Celular/fisiología , Colagenasas/efectos de los fármacos , Dexametasona/farmacología , Precursores Enzimáticos/efectos de los fármacos , Femenino , Fibrinolisina/antagonistas & inhibidores , Huesos Metatarsianos/efectos de los fármacos , Huesos Metatarsianos/embriología , Huesos Metatarsianos/metabolismo , Ratones , Técnicas de Cultivo de Órganos , Osteoclastos/efectos de los fármacos , Embarazo , Hormonas Tiroideas/farmacologíaRESUMEN
The most obvious proteolytic event controlled by the osteoclast is bone matrix removal in the resorption compartment. Here, however, we investigated whether matrix metalloproteinase (MMP) activity of the osteoclast might be involved in its migration to its future bone resorption site. We seeded either nonpurified or purified osteoclasts onto either uncoated or collagen-coated dentine slices and cultured them in the presence or absence of specific MMP inhibitors. When nonpurified osteoclasts were cultured on uncoated dentine, MMP inhibitors did not prevent pit formation, as previously reported. However, when collagen-coated dentine was used, pit formation was strongly inhibited by MMP inhibitors. The same results were obtained when performing these experiments with purified osteoclasts, thus demonstrating the ability of osteoclasts by themselves to migrate through collagen via an MMP-dependent pathway. This demonstration was confirmed by using collagen-coated invasion chambers. In addition, the invasions were not, or only slightly, inhibited by inhibitors of serine proteinases, cysteine proteinases, and carbonic anhydrase, though the latter two are well established bone resorption inhibitors that strongly inhibited pit formation. It is concluded that osteoclasts can migrate through collagen in the absence of other cells and that this migration relies on MMP activity, whereas other enzymes typically required for bone removal in the resorption compartment are not essential for migration. Some of the osteoclast MMPs might thus be relevant to the migratory/invasive activity of the osteoclast, rather than to its bone resorptive activity itself.
Asunto(s)
Movimiento Celular/efectos de los fármacos , Colágeno/fisiología , Metaloendopeptidasas/antagonistas & inhibidores , Osteoclastos/enzimología , Osteoclastos/fisiología , Aminoácidos de Cadena Ramificada/farmacología , Animales , Matriz Ósea/efectos de los fármacos , Matriz Ósea/enzimología , Resorción Ósea/enzimología , Células Cultivadas , Cisteína Endopeptidasas/fisiología , Metaloendopeptidasas/fisiología , Osteoclastos/efectos de los fármacos , Fenilalanina/análogos & derivados , Fenilalanina/farmacología , Conejos , Tiofenos/farmacologíaRESUMEN
Digestion of calvarial bone by osteoclasts depends on the activity of cysteine proteinases and matrix metalloproteinases (MMPs). It is unknown, however, whether these enzymes act simultaneously or in a certain (time) sequence. In the present study, this was investigated by culturing mouse calvarial bone explants for various time intervals in the presence or absence of selective low molecular weight inhibitors of cysteine proteinases (E-64, Z-Phe-Tyr(O-t-Bu)CHN2 or CA074[Me]) and MMPs (CI-1, CT1166, or RP59794). The explants were morphometrically analyzed at the electron microscopic level. All proteinase inhibitors induced large areas of nondigested demineralized bone matrix adjacent to the ruffled border of actively resorbing osteoclasts. The appearance of these areas proved to be time dependent. In the presence of the cysteine proteinase inhibitors, a maximal surface area of demineralized bone was seen between 4 and 8 h of culturing, whereas the metalloproteinase inhibitors had their maximal effect at a later time interval (between 16 and 24 h). Because different inhibitors of each of the two classes of proteolytic enzymes had the same effects, our data strongly suggest that cysteine proteinases attack the bone matrix prior to digestion by MMPs. In line with the view that a sequence may exist were differences in the amount of proteoglycans (shown with the selective dye cuprolinic blue) in the subosteoclastic demineralized areas induced by the inhibitors. In the presence of the cysteine proteinase inhibitor, relatively high levels of cuprolinic blue precipitates were found, whereas this was less following inhibition of metalloproteinases. These data suggested that cysteine proteinases are important for digestion of noncollagenous proteins. We propose the following sequence in the digestion of calvarial bone by osteoclasts: after attachment of the cell to the mineralized surface an area with a low pH is created which results in dissolution of the mineral, then cysteine proteinases, active at such a low pH, digest part of the bone matrix, and finally, when the pH has increased somewhat, MMPs exert their activity.
Asunto(s)
Matriz Ósea/enzimología , Resorción Ósea/enzimología , Cisteína Endopeptidasas/análisis , Metaloendopeptidasas/análisis , Osteoclastos/enzimología , Amidas/farmacología , Aminoácidos de Cadena Ramificada/farmacología , Animales , Matriz Ósea/efectos de los fármacos , Matriz Ósea/ultraestructura , Resorción Ósea/patología , Células Cultivadas , Cisteína Endopeptidasas/fisiología , Inhibidores de Cisteína Proteinasa/farmacología , Dipéptidos/farmacología , Concentración de Iones de Hidrógeno , Leucina/análogos & derivados , Leucina/farmacología , Metaloendopeptidasas/fisiología , Ratones , Morfolinas/farmacología , Osteoclastos/efectos de los fármacos , Osteoclastos/ultraestructura , Inhibidores de Proteasas/farmacología , Cráneo , Factores de TiempoRESUMEN
The identification of the plasminogen activator (PA) types present in bone and the regulation of their activity by parathyroid hormone (PTH) were investigated in cultures of fetal mouse calvariae with the use of either a chromogenic substrate or a zymographic assay. PA was detected essentially in the tissue extracts of the explanted bones, with only 1-2% of the total activity released in the surrounding culture media. From their electrophoretic behavior compared to PAs of other mouse tissues and from their response to a specific antibody raised against the tissue type PA (tPA), two major molecular species, of 70 and 48 kD were identified as tPA and urokinase (uPA), respectively, a third minor species of 105 kD being likely to correspond to complexes between tPA and an inhibitor; the culture fluids, moreover, contained enzymatically active degradation products of uPA of 42 and 29 kD. The PA activity of the bone extracts was only minimally affected by the addition of fibrinogen fragments to the chromogenic assays. PTH induced bone resorption and stimulated in parallel the accumulation of PA in the tissue; other bone-resorbing agents, 1,25-dihydroxyvitamin D3 and prostaglandin E2, had similar effects. Densitometric scanning of the zymograms of the bone extracts indicated that PTH stimulated only the production of tPA and had no effect on that of uPA. However, PTH also enhanced the release of uPA (both the 48 kD and the 29 kD forms) from the bones into the media. Although inhibiting bone resorption, calcitonin had no effect on the PTH-induced accumulation of PA in bone or on the release of tPA, but it prevented the PTH-induced accumulation of 29 kD uPA in the culture fluids. Thus these studies support the view that tPA and possibly also uPA may have a role in the physiology of bone; the nature of this role remains to be elucidated, however.
Asunto(s)
Huesos/enzimología , Hormona Paratiroidea/farmacología , Activador de Tejido Plasminógeno/metabolismo , Activador de Plasminógeno de Tipo Uroquinasa/metabolismo , Anticuerpos/inmunología , Resorción Ósea , Calcitonina/farmacología , Calcitriol/farmacología , Medios de Cultivo , Técnicas de Cultivo , Densitometría , Dinoprostona/farmacología , Ensayo de Inmunoadsorción Enzimática , Fibrinógeno/farmacología , Humanos , Activador de Tejido Plasminógeno/inmunología , Activador de Plasminógeno de Tipo Uroquinasa/inmunologíaRESUMEN
Difficulties in the geometrical definition and measurement of resorption pits is a major problem for the quantitative analysis of bone resorption by isolated osteoclasts cultured on bone or dentin substrates. In this study we developed an enzyme-linked immunosorbent assay (ELISA) for quantification of bone resorption in vitro, which specifically quantifies type I collagen fragments released into the culture medium by the resorptive action of bone cells cultured on slices of bone or dentin. A consistently high correlation between the formation of resorption pits and the release of antigenic collagen fragments was observed for isolated rabbit osteoclasts seeded at various densities and cultured for various periods on bovine, elephant, and human substrates. In a further support of the osteoclastic nature of the collagenolytic effects, a high consistency between pit formation and collagenolysis was also observed when the rabbit bone cells were cultured in the presence of very differently acting but typical inhibitors of pit formation, i.e., the carbonic anhydrase inhibitor acetazolamide, the cysteine proteinase inhibitor epoxysuccinyl-L-leucylamido-(4-guanodino)butane (E-64), the phosphatidyl-inositol 3-kinase inhibitor wortmannin, and the bisphosphonate ibandronate (BM 21.0955). In conclusion, the ELISA represents a simple, precise, and objective way to dynamically monitor bone resorption in vitro through quantification of the collagenolytic activity of isolated osteoclasts.
Asunto(s)
Resorción Ósea/patología , Colágeno/metabolismo , Ensayo de Inmunoadsorción Enzimática , Osteoclastos/metabolismo , Secuencia de Aminoácidos , Animales , Bovinos , Recuento de Células , Medios de Cultivo Condicionados , Epítopos , Hidrólisis , Técnicas In Vitro , Datos de Secuencia Molecular , Especificidad de la EspecieRESUMEN
In this study we investigated the role of bone lining cells in the coordination of bone resorption and formation. Ultrastructural analysis of mouse long bones and calvariae revealed that bone lining cells enwrap and subsequently digest collagen fibrils protruding from Howship's lacunae that are left by osteoclasts. By using selective proteinase inhibitors we show that this digestion depends on matrix metalloproteinases and, to some extent, on serine proteinases. Autoradiography revealed that after the bone lining cells have finished cleaning, they deposit a thin layer of a collagenous matrix along the Howship's lacuna, in close association with an osteopontin-rich cement line. Collagenous matrix deposition was detected only in completely cleaned pits. In bone from pycnodysostotic patients and cathepsin K-deficient mice, conditions in which osteoclastic bone matrix digestion is greatly inhibited, bone matrix leftovers proved to be degraded by bone lining cells, thus indicating that the bone lining cell "rescues" bone remodeling in these anomalies. We conclude that removal of bone collagen left by osteoclasts in Howship's lacunae is an obligatory step in the link between bone resorption and formation, and that bone lining cells and matrix metalloproteinases are essential in this process.
Asunto(s)
Desarrollo Óseo/fisiología , Huesos/citología , Animales , Enfermedades Óseas Metabólicas/metabolismo , Matriz Ósea/metabolismo , Remodelación Ósea/fisiología , Resorción Ósea/patología , Resorción Ósea/fisiopatología , Catepsina K , Catepsinas/deficiencia , Colágeno/metabolismo , Técnicas de Cultivo , Cisteína Endopeptidasas/metabolismo , Humanos , Metaloproteinasas de la Matriz/metabolismo , Ratones , Modelos Biológicos , Osteoclastos/citología , Osteoclastos/metabolismoRESUMEN
Bone resorption may generate collagen fragments such as ICTP and CTX, which can be quantified in serum and/or urine by using specific immunoassays, and which are used as clinical markers. However, the relative abundance of ICTP and CTX varies according to the type of bone pathology, suggesting that these two fragments are generated through distinct collagenolytic pathways. In this study, we analyzed the release of ICTP and CTX from bone collagen by the proteinases reported to play a role in the solubilization of bone matrix. Cathepsin K released large amounts of CTX, but did not allow a detectable release of ICTP. Conversely, the matrix metalloproteinases (MMPs) MMP-2, -9, -13, or -14 released ICTP, but did not allow a detectable release of CTX. Next we analyzed the release of ICTP and CTX from bone explants cultured in the presence of well-established inhibitors of these proteinases and of matrix solubilization. An inhibitor of cysteine proteinases including cathepsin K, inhibited the release of CTX, but not the release of ICTP. MMP inhibitors inhibited the release of ICTP, but also that of CTX, in agreement with the putative role of MMPs in the initiation of bone resorption in addition to matrix solubilization. Similarly the treatment of mice bearing bone metastasis with an MMP inhibitor led to a significant reduction of serum ICTP and CTX, and osteolytic lesions. We conclude that the generation of ICTP and CTX depends on different collagenolytic pathways. This finding may explain why these two markers may discriminate between different bone pathologies.
Asunto(s)
Resorción Ósea , Huesos/metabolismo , Colágeno/metabolismo , Fragmentos de Péptidos/metabolismo , Péptidos/metabolismo , Procolágeno/metabolismo , Anciano , Catepsina K , Catepsinas/metabolismo , Colágeno Tipo I , Técnicas de Cultivo , Femenino , Humanos , Metaloproteinasas de la Matriz/metabolismoRESUMEN
The participation of collagenase in bone resorption has been investigated by assaying the procollagenase extracted from fetal mouse calvaria cultured under a variety of conditions, and by evaluating its ability to degrade bone collagen. Procollagenase was found in two separate pools, one requiring demineralization for its extraction, the other not. Culturing the bones with PTH, 1,25-dihydroxyvitamin D3, prostaglandin E2, interleukin-1, tumor necrosis factor-alpha, catabolin, retinoic acid, or endotoxin (but not with heparin) induced resorption, enhanced lysosomal enzyme release, and markedly increased the procollagenase content of the second pool. The PTH-induced increase in procollagenase was dose dependent and paralleled the extent of calcium loss and lysosomal enzyme release. The increase in procollagenase was found in bone, periosteum, and sutures, where its distribution was similar to that of nonmineralized collagen. The increase in procollagenase was abolished by cycloheximide, but not by indomethacin, hydroxyurea, glucocorticoids, acetazolamide, bisphosphonates, or calcitonin. Calcitonin and bisphosphonates almost completely inhibited the PTH-induced Ca loss and lysosomal enzyme release, but only partially inhibited the PTH-induced loss of collagen. The latter was, however, completely prevented by the collagenase inhibitor, CI-1. CI-1 also partially inhibited the PTH-induced Ca loss. Moreover, collagen degradation occurred in PTH-precultured calvaria (but not in noncultured controls) when incubated in a buffer under nonviable and nondemineralizing conditions. This degradation was inhibited by collagenase inhibitors, either CI-1 or the natural tissue inhibitor of metalloproteinases. This work thus indicates that the resorption of fetal bone explants proceeds along with an accumulation of procollagenase, primarily within their nonmineralized matrix. Moreover the results suggest that collagenase is likely to participate in the degradation of the nonmineralized collagen of the bone explants. Whether it also participates in the degradation of the collagen of the mineralized matrix remains to be elucidated.
Asunto(s)
Resorción Ósea/efectos de los fármacos , Huesos/enzimología , Colagenasas , Precursores Enzimáticos/metabolismo , Colagenasa Microbiana/metabolismo , Acetazolamida/farmacología , Animales , Calcitonina/farmacología , Calcitriol/farmacología , Células Cultivadas , Cicloheximida/farmacología , Dinoprostona , Precursores Enzimáticos/biosíntesis , Feto , Heparina/farmacología , Hidroxiurea/farmacología , Interleucina-1/farmacología , Cinética , Ratones , Colagenasa Microbiana/biosíntesis , Organofosfonatos/farmacología , Osteoclastos/citología , Osteoclastos/efectos de los fármacos , Hormona Paratiroidea/farmacología , Prostaglandinas E/farmacología , Proteínas Recombinantes/farmacología , Tretinoina/farmacología , Triamcinolona/farmacología , Factor de Necrosis Tumoral alfa/farmacología , Factor de Necrosis Tumoral alfa/fisiologíaRESUMEN
The Arguello model of cancer metastasis to bone has been used extensively to study breast cancer-induced osteolytic disease. The effects of therapy on skeletal disease and on tumour burden in soft organs are traditionally measured using radiography and/or time-consuming histomorphometry, respectively. The purpose of this study was to develop a sensitive and efficient method for evaluating tumour burden in vivo using MDA-231 cells transduced with the E. coli lacZ gene (MDA-231BAG). Osteolysis was measured by radiography and tumour burden was measured histomorphometrically or biochemically. In untreated mice, measurements of tumour burden in bone extracts using human cytokeratin-associated tissue polypeptide antigen (TPA) ELISA or E. coli beta-galactosidase (beta-gal) activity immunoassay reflected the extent of osteolytic disease as measured by radiography; however, tumour load could be detected before onset of osteolysis. When monitoring the effect of therapy (0.2 mg/kg ibandronate/day), radiography alone proved to be insufficient. Mice treated with the bisphosphonate ibandronate from time of inoculation with cancer cells had no radiologically visible signs of osteolysis but significant tumour load was measured in the bone extracts using these assays. Furthermore, beta-gal activity could be used as a measurement of tumour load in soft organs, and unlike other human breast cancer markers expressed by the MDA-231 cells in vitro, beta-gal activity was detected in the serum of mice with progressive disease. In conclusion, we describe an efficient model of breast cancer-induced osteolysis to quantify the effect of therapy on disease load and distribution, which could be beneficial in evaluating novel therapies for the treatment of the disease.
Asunto(s)
Neoplasias Óseas/secundario , Neoplasias de la Mama/patología , Osteólisis , Animales , Biomarcadores de Tumor/sangre , Resorción Ósea/prevención & control , Difosfonatos/administración & dosificación , Difosfonatos/farmacología , Femenino , Humanos , Ratones , Ratones Desnudos , Trasplante de Neoplasias , beta-Galactosidasa/sangreRESUMEN
The effects of specific inhibitors of cysteine-proteinases ((Z-Phe-Ala-CHN2: benzyloxycarbonyl-phenyl-alanyl alanyl diazomethane and E-64: trans-epoxy-succinyl-L-leucylamido(4-guanidino)-butane) and collagenase and collagenase ((Cl-1: N-(3-N-benzyloxycarbonyl amino-1-R-carboxypropyl)-L-leucyl-O-methyl-L-tyrosine N-methylamide) have been tested on the osteoclastic resorption of dentine. Chick osteoclasts were cultured in the presence or absence of 12.5 microM Z-Phe-Ala-CHN2, 40 or 60 microM E-64, or 40 or 100 microM Cl-1 for 1 or 2 days. In addition, osteoclasts were cultured on oyster shell calcitostracum with or without 12.5 microM Z-Phe-Ala-CHN2. Specimens were studied by light microscopy to count cells and resorption features and by scanning electron microscopy (SEM) stereophotogrammetry for the measurement of the depths, plan-areas and volumes of resorption pits. The numbers, depths and volumes (but not the plan-areas) of the resorption pits in dentine were significantly reduced by Z-Phe-Ala-CHN2 and E-64. Thus, for a given plan-area, the volumes and the depths of resorption pits were smaller in these experimental groups compared with control dentine specimens. The overall inhibition of resorption was at least 75%. Cl-1 did not have this inhibitory effect on the numbers or sizes of resorption pits in dentine. When the oyster calcitostracum was used as a substrate for the osteoclasts, Z-Phe-Ala-CHN2 did not reduce the numbers or volumes of pits, but increased the plan-areas and prevented the formation of deeper pits.(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Resorción Ósea/efectos de los fármacos , Inhibidores de Cisteína Proteinasa , Colagenasa Microbiana/antagonistas & inhibidores , Osteoclastos/efectos de los fármacos , Animales , Embrión de Pollo , Técnicas de Cultivo , Cisteína Endopeptidasas/metabolismo , Dentina/metabolismo , Masculino , Colagenasa Microbiana/metabolismo , Osteoclastos/metabolismo , Ostreidae , BallenasRESUMEN
A pretreatment with (+)-catechin renders embryonic mouse calvaria in culture resistant to the action of bone resorbing agents, either parathyroid hormone (PTH), prostaglandin E2 or retinoic acid, and inhibits in a parallel way the enhanced excretion of N-acetyl-beta-glucosaminidase, a reference lysosomal enzyme, induced by these agents; it has, however, no effect on the small spontaneous leakage of lactate dehydrogenase from the explants. Moreover, the resorption induced in calvaria by a pretreatment with PTH or retinoic acid is inhibited by a further culture with catechin. This inhibition of bone resorption is discussed in relation with the collagen-stabilizing properties of (+)-catechin.
Asunto(s)
Benzopiranos/farmacología , Resorción Ósea/efectos de los fármacos , Catequina/farmacología , Animales , Calcio/metabolismo , Dinoprostona , Isoenzimas , L-Lactato Deshidrogenasa/metabolismo , Ratones , Técnicas de Cultivo de Órganos , Hormona Paratiroidea/farmacología , Prostaglandinas E/farmacología , Tretinoina/farmacologíaRESUMEN
Excessive matrix metalloproteinase activities have been implicated in the pathogenesis of intestinal anastomotic dehiscence, a serious and potentially life-threatening complication following gastrointestinal surgery. In this review, the properties of matrix metalloproteinases are summarized followed by presentation of clinical therapeutic interventions with synthetic matrix metalloproteinase inhibitors and novel experimental data on colon anastomosis repair that warrant exploration of these drugs in surgical colorectal patients.